Abstracts

INEQUITIES IN TRAVEL-TIME TO HIV TREATMENT IN AFRICA: A 3 COUNTRY COMPARISON

Background: UNAIDS has recently announced a new strategy “End Inequalities. End AIDS. Global AIDS Strategy 2021-2026”. Increased travel-time to health facilities has been associated with decreased treatment initiation and retention. We analyze data from the nationally representative Population-Based HIV Impact Assessment (PHIA) surveys from Eswatini, Malawi, and Zambia to identify inequities in travel-time to treatment.…

TRENDS IN TDR TO FIRST-LINE ANTIRETROVIRALS IN SPAIN: 2007-2021

Background: Treatment guidelines currently recommend resistance testing in the RT and protease of HIV as a part of the initial evaluation of HIV infected patients. Thus, it is of interest to evaluate the prevalence of drug resistance mutations (DRM) and, also of clinically relevant resistance. Here, we present data on trends in DRM and clinically…

HIV-EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES

Background: HEU infants are at risk for adverse metabolic, infectious, and neurodevelopmental outcomes when compared to HIV unexposed uninfected (HUU) infants. However, the relationships between maternal immunity in pregnant women with HIV (PWWH) and their HEU infants are largely unexplored. Proinflammatory immune pathways from PWWH and their HEU infants were examined in comparison to pregnant…

CHARACTERIZING THE ROLE OF MONOCYTES IN HIV NEUROPATHOGENESIS

Background: 15-40% of people with HIV (PWH) develop HIV associated Neurocognitive Impairment (HIV-NCI) despite viral suppression with ART. HIV-NCI is mediated, in part, by transmigration of infected CD14+CD16+ monocytes across the blood brain barrier (BBB), establishing a CNS viral reservoir. We showed that CD14+CD16+ monocytes from PBMC of PWH have increased transmigration across an in-vitro…

POPULATION IMPACT OF EXPANDING PrEP USAGE IN SOUTH AFRICA: MODEL COMPARISON ANALYSIS

Background: Long-acting injectable cabotegravir (CAB-LA) demonstrated superiority to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis (PrEP) in two clinical trials. It is recommended by WHO as an additional prevention choice for people at substantial risk of HIV infection. HIV Modeling Consortium and HPTN Modeling Center conducted a comparative modelling analysis of the…

SUSCEPTIBILITY SCREENING TO bNAbs GS-5423 AND GS-2872 IN ART-SUPPRESSED PARTICIPANTS

Background: Broadly neutralizing antibodies (bNAbs) display strong antiviral activity by targeting HIV Envelope (Env) with high potency and breadth. However, Env diversity can lead to natural resistance, creating challenges for the use of bNAbs as antiviral therapies, and posing the need to screen participants for susceptibility to bNAbs. We compared genotypic and phenotypic analyses to…

VIROLOGIC FAILURE AFTER ROUTINE SWITCHING TO DTG-BASED FIRST-LINE ART

Background: WHO recommends Dolutegravir (DTG) as the third drug in first-line antiretroviral therapy (ART) for people living with HIV (PLWH). Some pre-existing NRTI resistance mutations could lead to “functional” DTG monotherapy and thus increase the risk of DTG resistance. As resistance testing at the time of the switch is generally unavailable, there are concerns that…